Peptide Library

Human study PLS-00164

Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study.

Cross-sectional study · 76 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study.primary · Renal failure · 2023-12-01 · PMID 37133832 · DOI

Design and participants

Design
Cross-sectional study
Population
Peritoneal dialysis patients with end-stage kidney disease, assessed for malnutrition-inflammation-atherosclerosis (MIA) syndrome.
Conditions
Kidney failure, chronic, Peritoneal dialysis, Malnutrition-inflammation-atherosclerosis syndrome
Setting
Single-center pilot study
Planned enrollment (registry)
Not reported
Enrolled
76
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no intervention was administered.

    The authors concluded (paraphrased): Serum Tβ4 is lower in peritoneal dialysis patients with MIA syndrome, and the prevalence of MIA syndrome falls as serum Tβ4 levels rise.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin β4 was only measured as an endogenous biomarker and never given, so the study says nothing about the effects of administering it.
    • confounding: A cross-sectional association cannot establish causality; residual confounding is possible despite the adjusted models.
    • small or imprecise: Single-center pilot study with only 76 peritoneal dialysis patients.
    • abstract only: Only the abstract is available, and several p-values in it are truncated, which limits appraisal.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 37133832, abstract (Methods, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 37133832, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 37133832, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 37133832, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 37133832, abstract (Results, final sentence) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 37133832, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 37133832, title (title) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 37133832, abstract (Results, final sentence) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).